Aim: To investigate the effects of the transducer of ErbB-2.1 (TOB1) on the proliferation, migration and invasion of human lung cancer cells in vitro. Methods: Human lung cancer cell lines (95-D, A549, NCI-H1299, NCI-H1975, NCI-H661, NCI-H446, NCI-H1395, and Calu-3) and the normal human bronchial epithelial (HBE) cell line were tested. The expression levels of TOB1 in the cells were determined with Western blot and RT-PCR analyses. TOB1-overexpressing cell line 95-D/TOB1 was constructed using lipofectamine-induced TOB1 recombinant plasmid transfection and selective G418 cell culture. The A549 cells were transcend-transfected with TOB1-siRNA. MTT assay, flow cytometry and Western blot analysis were used to examine the effects of TOB1 on cancer cell proliferation and wound healing. Transwell invasive assay was performed to evaluate the effects of TOB1 on cancer cell migration and invasion. The activity of MMP2 and MMP9 was measured using gelatin zymography assay. Results: The expression levels of TOB1 in the 8 human lung cancer cell lines were significantly lower than that in HBE cells. TOB1 overexpression inhibited the proliferation of 95-D cells, whereas TOB1 knockdown with TOB1-siRNA promoted the growth of A549 cells. Decreased cell migration and invasion were detected in 95-D/TOB1 cells, and the suppression of TOB1 enhanced the metastasis in A549 cells. TOB1 overexpression not only increased the expression of the phosphatase and tensin homolog (PTEN), an important tumor suppressor, but also regulated the downstream effectors in the PI3K/PTEN signaling pathway, including Akt, ERK1/2, etc. In contrast, decreased expression of TOB1 oppositely regulated the expression of these factors. TOB1 also regulates the gelatinase activity of MMP2 and MMP9 in lung cancer cells.
Introduction
As one of the leading causes of cancer mortality in the world and the most common occupational cancer, lung cancer is becoming the biggest challenge for basic science [1] . Despite advances in surgery, radiotherapy, and chemotherapy, the mortality rate of lung cancer has not been substantially reduced over the past decades, largely because of potential metastasis. Metastasis is one of the most lethal attributes of cancer, responsible for about 90% of human cancer deaths [2] . Lung cancer metastasis involves a complex series of steps, including cellular migration, local invasion, dissemination, and angiogenesis. The inhibition of one of these processes can substantially prevent secondary tumors from spreading in the body [3, 4] . The tumor suppressor protein, which functions in cell cycle regulation, apoptosis induction, DNA damage repair, and metastasis inhibition, is a potential therapeutic target in lung cancer [5] [6] [7] . One of the promising examples is p53, whose mutation has been detected in 90% of small cell lung cancers and in 50% of non-small cell lung cancer. In 2006, Cristofanilli et al [8] reported that adenovirus mediates p53 overexpression, Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1)
which induces cell apoptosis in p53-null cells. These data documented a safety profile, encouraging clinical trials of adenovirus-mediated p53 in the therapy of lung cancer. However, evidence concerning other tumor suppressors thought to be responsible for lung cancer carcinogenesis, migration, and invasion still needs to be clarified. The transducer of ErbB-2.1 (TOB1) gene was initially identified as a member of the anti-proliferative TOB/BTG (transducer of ErbB-2/B-cell translocation gene) protein family, which was first discovered in the 1990s [9] . In mammalian cells, this family consists of BTG1, BTG2, BTG3, BTG4, TOB1, and TOB2. All the protein products of the family members possess the potential ability to restrain cell growth [10] [11] [12] [13] . Carcinogenesis and tumor progression in lung, liver, and lymph nodes were observed in mice lacking TOB1 [14] . Furthermore, TOB1 deletion and dysfunction were also reported in human malignancies [15, 16] . These studies suggest that TOB1 acts as a tumor suppressor gene. Accumulating studies have also found that TOB1 might inhibit cell proliferation through its intervention in oncogenic pathways, including the epidermal growth factor and the TGF-β/Smad signal pathways [17] [18] [19] . Although TOB1 expression is reduced in clinical lung cancer samples [15] , the effects of TOB1 on lung cancer proliferation and metastasis in vitro are poorly understood. The signaling pathways or the related mechanisms remain unclear.
In the present study, using Lipofectamine-mediated TOB1 recombinant plasmid and siRNA transfection of lung cancer cell lines, the effects of TOB1 on lung cancer proliferation, invasion, and migration are investigated in vitro. The possible pathways involved in its regulation of lung cancer tumorigenesis and metastasis are explored.
Materials and methods

Cell culture
The normal human bronchial epithelial (HBE) cell line and  eight human lung cancer cell lines (95-D, A549, NCI-H1299,  NCI-H1975, NCI-H661, NCI-H446, NCI-H1395, and Calu-3) were purchased from American Type Culture Collection (Manassas, VA, USA). Calu-3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM). The other cells were seeded onto tissue culture dishes containing RPMI-1640 supplemented with 10% fetal calf serum (FCS), L-glutamine (5 mmol/L), non-essential amino acids (5 mmol/L), penicillin (100 U/mL), and streptomycin (100 U/mL) (Invitrogen, Carlsbad, CA, USA), at 37 °C in a humidified 5% CO 2 atmosphere.
Plasmids, siRNAs, and transfection
The full-length human TOB1 cDNA was derived using polymerase chain reaction (PCR), using specific primers designed according to the TOB1 reference sequence from GenBank (NM_005749.2), and then cloned into the eukaryotic expression vector pcDNA3.0 (Invitrogen, Carlsbad, CA, USA). Three siRNA that target TOB1 mRNA and control (scrambledsequence) siRNA were designed and synthesized by Invitrogen. For stable transfection, the cells were transfected using Lipofectamine 2000
TM . After an additional 24-h incubation, 500 µg/mL G418 (Sigma-Aldrich, MO, USA) was applied. After four weeks, the cell clones that overexpressed TOB1 were identified and obtained. Treatments with siRNA were performed as previously described [20] . Subconfluent lung cancer cells were transfected with each siRNA (40 nmol/L) using Lipofectamine™ RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA). Before the start of the following experiment, the cells were incubated for another 48 h. The TOB1 inhibition efficiency by siRNA was determined using Western blot analysis. siRNA #1 exhibited about 30% decreased TOB1 expression, whereas no effect on TOB1 expression was observed in the control siRNA. Therefore, siRNA #1 was selected for further studies. The sequences for TOB1-siRNA #1 is as follows (5′ to 3′): GCUGUAAGCCCUACCUUCATT UGAAGGUAGGGCUUACAGCTT
Cell viability assay
Cell proliferation was determined using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) viability assay, the most commonly used assay for determining cell growth and death. The MTT survival assay has been described in detail in previous studies [21] . Exponentially growing cells were recultured (5000 cells/well) overnight in 96-well tissue culture plates. Up to 20 μL of MTT (Sigma-Aldrich, MO, USA) was directly added to the media in each well, with a final concentration of 2 mg/mL. After 4-h incubation, the medium containing MTT was discarded, and 120 μL of dimethyl sulfoxide was added for 10 min. The absorbance was measured using an enzyme-linked immunosorbent assay reader at 570 nm, with the absorbance at 630 nm as the background correction. The cell viability was expressed as the percentage of untreated controls. All experiments were performed at least three times.
Cell cycle assays
The cells were removed with trypsin and collected into centrifuge tubes together with the culture medium. All the contents were centrifuged for 5 min at 1800×g. The supernate was poured out, washed once with 1×phosphate-buffered saline (PBS), and centrifuged for another 5 min. The cells were finally fixed with 5 mL of pre-cooled 70% ethanol for at least 4 h. The fixed cells were centrifuged and washed with 1×PBS. After centrifugation, the cell pellets were resuspended in 500 μL of propidium iodine (10 μg/mL) containing 300 μg/mL RNase (Sigma-Aldrich, USA). The cells were then incubated on ice for 30 min, and then filtered with a 53-μm nylon mesh. The cell cycle distribution was calculated from 10 000 cells using ModFit LT software (Becton Dickinson, CA, USA) using FACS Calibur (Becton Dickinson, San Jose, CA, USA).
Transwell invasion assay
The invasion assay was carried out using Transwell (Millipore, Billerica, MA, USA), as previously described [20] . The filter surfaces (8 µm pore size) of the Transwell plates were uniformly coated with 25 mg of Matrigel overnight at 4 °C before the experiment. The lower chamber was filled with culture 
Wound healing assay
In vitro cell migration was assessed using the scratch wound assay. The cells were subcultured onto six-well tissue culture plates to confluent cell monolayers using culture medium containing 10% FCS. The "wounds" were carefully created manually on the monolayers using sterile pipette tips, and the cellular debris was washed off with the desired medium. Phase contrast images of certain fixed positions in the wound area were taken at 0, 24, and 48 h after scratching using Olympus CKX41 microscope with a digital camera. In the images, the edge of the initial wound area was marked with lines using Image-Pro ® Plus software (Media Cybernetics, Carlsbad, CA, USA). The edge of the initial wound area was overlaid with the image taken at 24 and 48 h after scratching. The number of cells migrating into the initial wound area was counted at 24 and 48 h after scratching. The data were obtained from three independent assays.
Western blot and immunoprecipitation (IP)/immunoblot analyses Cell lysates were prepared and Western blot analysis was performed as previously described [22] . Equal aliquots of total cell protein (50 µg per lane) were electrophoresed on sodium dodecyl sulfate (SDS)-polyacrylamide gels, transferred onto polyvinylidene fluoride (PVDF) membranes, and then blotted using the following primary antibodies (Santa Cruz Biotech, Santa Cruz, CA, USA, 1:1000 dilution):
E-cadherin (G-10); and secondary antibody horseradish peroxidase-labeled goat anti-mouse (GAM-007) and goat antirabbit (SC-2004) IgG. For the IP/Western blot, 1 mg lysate was immunoprecipitated with 1 µg of anti-TOB (E-1) antibody at 4 °C overnight. Protein A-Sepharose beads were added and incubated at 4 °C for 2 h, and the protein-bead complex was washed 5 times with radioimmunoprecipitation assay lysis buffer. The SDS-polyacrylamide gel electrophoresis (PAGE) was then performed to separate the immunoprecipitates. The anti-TOB1 (H-18) and anti-PTEN (N-19) antibodies were applied for immunoblot. The protein bands were visualized using an enhanced chemiluminescence system (Union Bioscience Corporation, Hangzhou, China) with prestained markers as molecular size standards. The densitometry of the protein bands was quantified with Quantity One (Bio-Rad, Hercules, CA, USA), and the values were expressed relative to β-actin (control for loading and transfer). At least three independent experiments were performed for each cell type studied.
Semiquantitative reverse transcription (RT)-PCR analysis mRNA expression was determined using semiquantitative RT-PCR assays. The PCR reaction conditions and cycle numbers were rigorously adjusted so that each reaction occurred within the linear range of amplification. The detailed methods for RNA isolation, cDNA synthesis, and RT-PCR analyses have been previously described [23] . For specific intent genes, the PCR primers were as follows: GAPDH sense, 5′-CAAC-TACATGGTCTACATGTTCC-3′, anti-sense, 5′-CAACCTG-GTCCTCAGTGTAG-3′; TOB1 sense, 5′-GGATCGACCCATTT-GAGGTTTCT-3′, anti-sense, 5′-CTACCCAAGCCAAGC-CCATACAG-3′; PTEN sense, 5′-AGACCATAACCCAC-CACA-3′, anti-sense, 5′-TTGACGGCT CCTCTACTG-3′. The PCR products were analyzed via electrophoresis through 1% agarose gels containing 0.1 mg/mL ethidium bromide (EB). The gels were photographed under ultraviolet light. The mRNA expression levels were quantified by densitometry of the cDNA bands using software Quantity One (Bio-Rad, Hercules, CA, USA). At least three independent experiments were performed for each cell type studied.
Gelatin zymography assay
The MMP-2 and MMP-9 activity of the supernates of lung cancer cells 95-D transfected or untransfected with TOB1 recombinant plasmid, as well as the RNAi-treated A549 cells, were identified using gelatin zymography assay as previously described [24] . At 24 h after transfection, all the cells were seeded onto 6-well plates at a final density of 3.0×10 5 cells/well. The supernatants were harvested after 24 h of additional incubation, and the conditioned media were collected by centrifugation at 13 000 r/min for 5 min to remove the debris. The concentrations of the samples were quantified using bicinchoninic acid assay (Beyotime Institute of Biotechnology, Haimen, China). Then, 20 µg of each protein sample was loaded under non-reducing conditions onto 10% SDSpolyacrylamide gel containing 500 µg/mL gelatin (Amresco, Slon, OH, USA). After electrophoresis under 165 V for 1.5 h, the gels were washed twice using washing buffer (50 mmol/L Tris-Cl pH 7.6, 10 mmol/L CaCl 2 ) with 2.5% Triton X-100 for 30 min. Then, the gels were incubated overnight in zymography developing buffer containing 50 mmol/L Tris-HCl, pH 7.5, 10 mmol/L CaCl 2 , 150 mmol/L NaCl, and 0.02% NaN 3 at 37 °C. Then, 0.05% Coomassie Brilliant Blue R-250 was utilized for gel staining, followed by destaining with a solution containing 30% methanol and 10% acetic acid. The gelatinase activity of the matrix metalloproteinases (MMPs) was then visualized as clear bands against the blue-stained background,
Acta Pharmacologica Sinica npg and the density of the bands was analyzed using Quantity One software. At least three individual experiments were conducted with independent protein samples.
Statistical analysis
The data are presented as means and standard deviations (SD). Statistical comparisons of the experimental results between the treated group and the control group were made using two-tailed Student's t-test. All statistical tests were performed using SPSS version 17.0. P value ≤0.05 between groups was considered significant.
Results
TOB1 expression is decreased in eight lung cancer cell lines TOB1 plays a role in suppressing the carcinogenesis of cancers, such as lung, thyroid, and breast cancers. However, the functional role of TOB1 in lung cancer has not yet been fully explored. To investigate the effect of TOB1 on proliferation and metastasis of lung cancer cells, the TOB1 expression levels in the eight lung cancer cell lines and in the normal bronchial epithelial cell line HBE were first analyzed using Western blot analyses and RT-PCR assays. As shown in Figure 1 , the levels TOB1 protein and mRNA expression levels all decreased in the eight lung cancer cell lines, although at different levels. Compared with the immortalized normal epithelial cell line HBE, TOB1 mRNA expression decreased from 10% to 90% in almost all of the eight lung cancer cell lines (P<0.05, Figure  1A and 1C). Similar results were confirmed in TOB1 protein expression, as shown in Figure 1B and 1D, wherein the TOB1 protein levels decreased from 100% in the HBE cells to 20% to 80%. These in vitro data confirmed the findings of previous studies by Iwanaga et al [15] that reducing TOB1 expression is an important event in lung cancer.
Ectopic expression of TOB1 regulates the proliferation of human lung cancer cells through alternation of the cell cycle According to gain-of-function and loss-of-function approaches, the lung cancer cell lines 95-D and A549 were selected as model systems because 95-D cells express almost-deleted TOB1, whereas A549 cells express moderate TOB1. Using Lipofectamine and G418-mediated plasmid stable transfection, multiple clones stably transfected with TOB1 were selected and confirmed through RT-PCR and Western blot analysis in 95-D/TOB1 (Figure 2A ). To investigate whether downregulated TOB1 expression enhances the aggressiveness of lung cancer cells, three different siRNA that target TOB1 and a control siRNA with a random sequence were generated and induced into A549 cells by transcend transfection. The efficacy of the siRNA was confirmed ( Figure 2B ). siRNA #1 efficiently reduced TOB1 expression in both the mRNA and protein level; thus, it was selected for further studies.
MTT viability assays were conducted to elucidate the potential biological effects of TOB1 in lung cancer cells. As shown in Figure 2C , the 95-D/TOB1 transfectants displayed about 50% reduction in proliferation rate compared with the "mock"- Sub-confluent proliferating cells were stained with propidium iodide and subjected to FACS analysis to determine the cell cycle distribution. (E) In the 95-D cells, TOB1 overexpression increased cyclin B1 expression, and negatively regulated the expression of cyclin D1, cyclin E, and CDK2. TOB1-siRNA transfection increased the expression of cyclin D1 and cyclin E, but slightly reduced cyclin B1 expression. The cells were harvested using trypsin and centrifugation. Equal aliquots of the total protein (50 µg) were analyzed by SDS-PAGE and blotted to detect cyclin B1, cyclin D1, and cyclin E protein expression. The protein expression was expressed as fold changes in band density, with β-actin as the loading control. All the experiments were performed independently at least three times. The functional role of TOB1 expression on cell cycle modulators was further investigated. The alterations in the different cyclins in TOB1-overexpressing or siRNA-TOB1 lung cancer cells were evaluated and compared with the parental or "mock" cells using Western blot analysis. Figure 2E shows that cyclin B1 expression increased three-fold in the 95-D/ TOB1 cells, but remarkably decreased in the siRNA-TOB1 A549 cells. The expression levels of cyclin E, CDK2, and cyclin D1 were significantly suppressed in the 95-D/TOB1 cells. In contrast, cyclin E and cyclin D1 expression were both increased in the A549/siRNA-TOB1-transfected cells. These results suggest that TOB1 might partly participate in cell cycle progression regulation by adjusting cyclin expression.
Alteration of the aggressiveness of lung cancer cells by TOB1 protein A critical event in tumor metastasis and progression is the ability of tumor cells to invade the extracellular matrix, allowing tumor cells to move beyond the restrictions of the primary tumor environment. To examine the competence of cells to invade through biological matrices in vitro, Transwell assay was carried out as described previously [20] . The results show that compared with the parental cells, amplified TOB1 expression vigorously inhibited the ability of the 95-D cells to invade through the filter coated with Matrigel. As shown in Figure  3A , the invasion rate of 95-D/TOB1 cells decreased by more than 80% corresponding to the parental and vector-transfected cells (t=68.56; P<0.05). In contrast, the invasion rate of A549 cells transfected with TOB1-siRNA increased by 2.5-fold (t=5.17; P<0.05) in contrast to the control cells ( Figure 3B ).
To determine whether the decreased invasiveness caused by TOB1 is associated with cell motility, the effect of TOB1 on cell migration capacity was analyzed using a wound healing assay [25] . The cells were scratch-wounded with sterile pipette tips and post-incubated for an additional 48 h. Figure 3C and 3D show that cell flattening and spreading along the edges of the wound were significantly more obvious in the A549/ siRNA cells than in the A549 cells (t=6.51; P<0.05), and were significantly lesser in 95-D/TOB1 cells than in the parental lung cancer cells (t=5.93; P<0.05).
Taken together, these results indicate that TOB1 gene expression significantly inhibits cell invasion and migration in vitro, and the knockdown of TOB1 conversely increases the ability of lung cancer cells to invade and migrate.
TOB1 mediates anti-metastasis effects through alterations of PTEN-mediated modulation of downstream signaling RT-PCR and Western blot analysis were utilized to identify additional targets of TOB1 that might be involved in downregulating lung cancer metastasis. PTEN, an important tumor suppressor mutated in a wide range of malignancies second only to p53, which is a central negative regulatory factor of epidermal growth factor receptor (EGFR) downstream of phosphoinositide 3 kinase (PI3K)-Akt (Akt8 virus oncogene cellular homolog) pathway. It plays a key role in cell proliferation, survival, and malignant transformation by regulating the mitogen-activated protein kinase (MAPK) and the PI3K/Akt and integrin-focal adhesion kinase (FAK) pathways. Recent studies have investigated several signaling pathways, such as MAPK and Akt, through which TOB1 conducts its tumor suppressor activity. In lung cancer, the functional pathways of TOB1 remain to be elucidated.
In the present study, RT-PCR was used to detect the effects of TOB1 on PTEN mRNA expression. TOB1 overexpression in the 95-D cells increased PTEN mRNA expression up to twofold in the control cells, whereas PTEN mRNA was reduced in the TOB1-siRNA-transfected A549 cells ( Figure 4A ). Western blot analysis was then conducted to identify the effects of TOB1 on the PI3K/PTEN pathways. The results show that TOB1 overexpression slightly decreased EGFR expression, thereby significantly suppressing the expression of downstream effecters Akt and ERK1/2, but had no obvious effects on the expression of these proteins. Reduced NF-κB (p65) and increased IκB-α phosphorylation were observed in the 95-D/TOB1 cells. TOB1 overexpression amplified E-cadherin expression and slightly downregulated α-/β-/γ-catenin (Figure 4B ). In addition, decreased MMP-2 and MMP-9 expression were also detected in the 95-D/TOB1 cells. In the TOB1-knockdown A549 cells, the contradictory effects on almost all these downstream factors were confirmed, as shown in Figure  4C These results reveal the ability of TOB1 to regulate most of the important downstream factors of the PI3K/PTEN signal pathway; therefore, the potential interaction between PTEN and TOB1 was further examined through an IP/immunoblot assay. The results indicate that the presence of PTEN protein in the TOB1 IP of the A549 cells containing the wild-type PTEN gene and moderate TOB1 gene expression, as shown in Figure 4E . In the TOB1-suppressed A549 cells, this proteinprotein association was still observed, but to a lesser extent. Neither PTEN nor TOB1 was found in the normal mouse IgG IP, which was the negative control for the IP assay (data not shown). The results imply that TOB1 is actually associated with PTEN in the A549 cells.
Discussion
Recently, accumulated evidence has indicated that the TOB1 gene is involved in the negative regulation of cell growth and functions as a tumor suppressor [26] [27] [28] . Alterations in TOB1 expression have been reported in a variety of human malig- prepared, and 50 µg of proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against EGFR, PTEN, TOB1, p-AKT, AKT, p-ERK1/2, ERK1/2, NF-κB, p-IκB-α, E-cadherin, α-catenin, β-catenin, and γ-catenin. (C) A549, A549/control siRNA, and A549/siRNA-TOB1 cells were harvested, and equal aliquots of the protein were subjected to a Western blot assy. The expression and activity of specific downstream factors in the PI3K/PTEN pathway were detected. The expression levels are displayed as fold changes in band density. [26] . In human lung cancer, in 2003, Iwanaga et al [15] reported reduced TOB1 expression in most of his 43 clinical specimens, but the exact biological effects of TOB1 on lung cancer carcinogenesis and progression remain unclear. In the present study, based on gain-of-function and loss-of-function principles, the roles of TOB1 in lung cancer cells have been demonstrated and TOB1-mediated downstream signaling pathways have been preliminarily explored. First, the variously decreased TOB1 mRNA and protein expression was revealed in eight lung cancer cell lines in contrast to the normal HBE cell line. These in vitro data confirm the findings of Iwanaga et al [15] that suppressed TOB1, which may be a tumor suppressor, is an important factor in human lung cancer cells.
One of the essential functions of tumor suppressors is to suppress tumor growth effectively by negatively regulating the cell cycle and/or inducing apoptosis [29] [30] [31] . Despite cell cycle regulation and apoptosis induction, several tumor suppressors are involved in preventing tumor cells from dispersing, blocking loss of contact inhibition, and inhibiting metastasis [32] [33] [34] [35] . We demonstrated for the first time that TOB1 overexpression significantly inhibits the ability of the highly invasive lung cancer cell line 95-D to invade through an artificial basement membrane and prevents cell migration in vitro. For the less invasive A549 cells, the partial knockdown of TOB1 by siRNA significantly promotes their invasiveness and migration in vitro.
In lung cancer, one of the well-studied pathways is EGFR and its downstream signaling cascade, which is involved in cellular proliferation, apoptosis, and metastasis [36] . The EGFR pathway has already been clinically accepted as a therapeutic target in advanced non-small cell lung cancer and other solid tumors in recent years [37] . Principle data suggest that EGFR heterodimer or homodimer formation induced by ligand binding activates the intracellular tyrosine kinase domain, consequently inducing additional downstream pathways via PLC-γ, MAPK, and PI3K, and finally affecting cell survival and metastasis through these downstream cascades [38] [39] [40] . In the current study, TOB1 overexpression reduced EGFR expression, whose phosphorylation is involved in MAP kinase signaling activation [41, 42] . Significantly decreased MAPK (ERK1/2 T185+Y187+T202+Y204) and Akt (Ser473) activity was observed in TOB1-transfected 95-D cells. Conversely, increased EGFR, MAPK, and Akt activity was observed in TOB1-knockdown A549 cells. Drastically reduced NF-κB (p65) and increased phosphorylation of IκB-α were observed in TOB1-overexpressing 95-D cells. In contrast, TOB1-siRNA promoted NF-κB expression and suppressed IκB-α phosphorylation. These results are correlated with the findings of Kojima et al [43] that the activation NF-κB stimulates invasion and metastasis via its regulation of MMP and cyclin D1 expression. We also found that variations in cellular TOB1 protein profoundly affect the expression of E-cadherin, α-, β-, and γ-catenin. Meanwhile, α-, β-, and γ-catenin bind to the highly conserved intracellular cytoplasmic tail of E-cadherin, and the catenin/cadherin complexes play important roles in mediating cellular adhesion [44] [45] [46] . Aside from its biological function, when not complexed with cadherins, β-catenin is an important downstream factor in the Wnt/β-catenin pathway [47, 48] , which can interact with transcription factors and regulate gene transcription; thus, it is involved in the regulation of proliferation and differentiation. The negative regulation of the expression of β-catenin and the downstream factors of Wnt/β-catenin pathway by TOB1 inhibited β-catenin transcriptional activity [49] . In the 95-D/TOB1 and A549-siRNA TOB1 cells, varied MMP-2 and MMP-9 expression and activity is responsible for the degradation of extracellular matrix components, including collagen, gelatin, fibronectin, laminin, and proteoglycans [50] [51] [52] . Thus, suppression of β-catenin-regulated transcription, which induces the expression of proliferative and progressive genes such as cyclin D1 and MMPs via the PI3K/PTEN pathway, may at least mediate the anti-proliferative and anti-metastasis function of TOB1 in lung cancer cells [53, 54] . In addition, the solid protein-protein interaction between TOB1 and PTEN in human lung cancer A549 cells, aside from the expression regulation effects of TOB1 on PTEN, is shown for the first time. These results provide several clues to outline the signal cascades and specific targets of TOB1-related proliferation and metastasis regulation in lung cancer cells ( Figure  5 ).
In conclusion, TOB1 is expressed in normal HBE cells, and the reduction of TOB1 expression is a common event in eight lung cancer cell lines. TOB1 functions as a tumor suppressor in NSCLC 95-D and A549 cells by modulating EGFR and its downstream signaling pathways through the direct or indirect interaction with the key tumor suppressor PTEN [55, 56] . However, whether the biological effects of TOB1 in lung cancer cells are triggered by its regulation on PTEN expression as a transcription factor or by its effect on PTEN phosphatase activity remain unclear. Whether TOB1 affects PTEN through other mechanisms, such as PTEN phosphorylation, ubiquitination, acetylation, or oxidation, in terms of carcinogenesis and progression is unknown. Further studies on the involvement of TOB1 in lung cancer carcinogenesis and progression are necessary; these will allow the development of more accurate theories to guide therapeutic practice. Figure 5 . TOB1 was involved in regulation of tumor growth and metastasis via the PI3K/PTEN signaling pathway. The binding of EGF to the corresponding EGF receptors activates PI3K and downstream signaling pathways, including Akt and ERK/p38 MAPK, leading to the activation of NF-κB gene expression. Consequently, the expression of cyclin D1 and MMPs are increased, resulting in the promotion of lung cancer tumorigenesis and metastasis. Despite its activation of NF-κB, Akt can also inhibit β-catenin expression, which plays an important role in mediating cellular adhesion together with α-and γ-catenin/cadherin complexes. In the present study, TOB1 was identified as a negative regulator of EGFR expression, increasing the expression of PTEN, which functions as the central negative regulator of the PI3K/AKT pathway in controlling tumorigenesis and metastasis. The protein-protein interaction between TOB1 and PTEN was detected for the first time in cultured lung cancer cells; hence, TOB1 may be a regulator of PTEN activity.
